An observational study in Parkinson Disease, sponsored by University College, London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by University College, London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Parkinson Disease by University College, London — 4 open to participants now, 4 under way, 2 of them phase 3. Parkinson Disease · University College, London.
Among the 16 studies in Parkinson Disease by University College, London, this one is one of 2 that started in 2020, is one of 4 observational ones, and was the 15th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →4 of the 16 studies in Parkinson Disease by University College, London are open now, in 1 country. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 30+
University College, London · Sites in United Kingdom
Ages 35–75
University College, London · Sites in United Kingdom
Ages 16+ · Healthy volunteers
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 4
First in 2010; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 56 across the 12 interventional studies, 1,080 across the 4 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University College, London is the lead sponsor of 652 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
1 of the studies in Parkinson Disease by University College, London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02760108University College, LondonParkinson's Families Project | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Parkinson Disease by University College, London, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PD Frontline (part of RAPSODI GD) is an online study observational study for People with Parkinson's. The aims are to better understand the genetic nature of Parkinson's and to connect participants to clinical trials and studies, particularly those with a genetic focus.
To do this, participants are offered genetic sequencing for two common genetic risk factors for Parkinson's Disease, the GBA1 and LRRK2 gene, with an at-home sample collection kit. Return postage is free.
PD Frontline is an online one-time questionnaire based study with the purpose of identifying potential candidates for gene targeted trials and observational studies. The study also seeks to better characterise GBA1 risk factors for Parkinson's Disease.
Once the questionnaire is completed, the participant is sent a sample collection kit in the post for use in genetic testing. The genes tested for are GBA1, the most common risk factor gene for Parkinson's, and LRRK2.
Once tested and where consent is in place, the participant is informed of their results and kept up-to-date with any studies or trials for which they may be eligible. Individuals identified to have genetic variants are contacted by the team to discuss, all participants are sent a report via their study profile.
Participants are kept up-to-date with any study outcomes via newsletters.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Randomly selected population, recruited via established NHS sites and self-referral to the website.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Genotype of participants
The primary outcome of the study is to genotype the GBA1 gene, obtained with Oxford Nanopore long read sequencing.
Time frame: 20 years
Started Feb 2020 (actual). Primary completion is estimated for Jan 2028, 94 months after the start.
Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 94 months is above that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2025 → Jan 2028, on Oct 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.